ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,312.51
-0.91%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Viracta Therapeutics Inc (VIRX)

  7. Viracta Therapeutics Inc (VIRX) Noticias

VIRX Viracta Therapeutics Inc

0.8102
-0.0298 (-3.55%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Viracta Therapeutics Inc VIRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0298 -3.55% 0.8102 23:00:07
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.8212 0.80 0.84 0.8102 0.84
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
15/4/202407:00GLOBEViracta Therapeutics Announces Positive Topline Nana-val..
01/4/202407:30GLOBEViracta Therapeutics to Present Topline Nana-val Results..
07/3/202416:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202415:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202415:12EDGAR2Form 8-K - Current report
07/3/202415:05GLOBEViracta Therapeutics Reports Fourth Quarter and Full Year..
29/2/202407:00GLOBEViracta Therapeutics Announces Completion of Second-Stage..
27/2/202419:40EDGAR2Form 144 - Report of proposed sale of securities
27/2/202418:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202420:04EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202415:05GLOBEViracta Therapeutics to Present at the Oppenheimer 34th..
04/1/202407:00GLOBEViracta Therapeutics Provides Clinical Update and Outlook..
12/12/202307:00GLOBEViracta Therapeutics Announces Orphan Drug Designation..
04/12/202315:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202307:30GLOBEViracta Therapeutics Announces Interim Data from Phase 1b/2..
28/11/202318:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202318:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202316:30EDGAR2Form 8-K - Current report
09/11/202315:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202307:30EDGAR2Form 8-K - Current report
09/11/202307:30GLOBEViracta Therapeutics Reports Third Quarter 2023 Financial..
07/11/202315:15GLOBEViracta Therapeutics to Present at Upcoming Investor..
04/10/202306:01EDGAR2Form 8-K - Current report
04/10/202306:00GLOBEViracta Therapeutics to Host R&D Day Highlighting Nana-val..
05/9/202308:00GLOBEViracta Therapeutics to Host R&D Day on October 4, 2023
29/8/202317:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202317:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202315:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202315:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202315:05GLOBEViracta Therapeutics Announces New Employment Inducement..
16/8/202316:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/8/202315:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202307:02EDGAR2Form 8-K - Current report
14/8/202307:00GLOBEViracta Therapeutics Reports Second Quarter 2023 Financial..
08/8/202307:30GLOBEViracta Therapeutics Announces Publication in Blood Advances..
07/8/202306:36EDGAR2Form 8-K - Current report
07/8/202306:30GLOBEViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D...
28/6/202307:00GLOBEViracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves..
31/5/202315:15GLOBEViracta Therapeutics to Present at the Jefferies Healthcare..
11/5/202315:05GLOBEViracta Therapeutics to Present at the RBC Capital Markets..
08/5/202315:05GLOBEViracta Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
VIRX
Viracta Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados